MPS to acquire US healthcare tech firm Unbound Medicine for USD 16.5M

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

MPSLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹1878.00

prior close

₹1929.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+1.5% vs market

Printing & Publication peers, median of 6sector+0.9%-0.6% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 0.6 pts less than its Printing & Publication peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.6

10m

-2.7

15m

-2.5

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-1.3+1.5+0.9-0.6

Next day

-5.0+2.4-7.4+3.8-8.8

-6.4+3.8-10.2+3.1-9.5

-11.9+2.7-14.6+2.7-14.6

-13.3+1.9-15.2-0.1-13.2

-9.7+4.6-14.2+5.5-15.2

-10.1+5.1-15.2+4.0-14.2

15d

-15.4+2.1-17.5+0.2-15.6

-21.2-2.1-19.1-2.6-18.6

-12.1-6.4-5.7-12.4+0.3

-13.5+9.5-23.0-5.4-8.0

UpDownMarket · Nifty Microcap 250Sector · Printing & Publication peers, median of 6Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

MPS North America LLC, wholly owned subsidiary of MPS Limited, to acquire 100 percent of US based Unbound Medicine Inc for USD 16.50 million in cash. Unbound offers healthcare learning and clinical decision support platforms, serving 480 plus institutions with about 97 percent gross retention. FY24 revenue was USD 8.88 million. Deal to close by 10 Feb 2026. Marks MPS entry into healthcare and medical IT segment, adding recurring revenue and AI capabilities.

Likely market impact

Strategic entry into healthcare tech adds a sticky recurring revenue business and supports Vision 2027 growth plan. Deal size is modest.